UNSPSC 51412010: Mefenidil

This classification denotes a vasodilating agent with the molecular formula C12H11N3, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 74WY8560J7, chemically known as 1h-imidazole-4-acetonitrile, 5-methyl-2-phenyl- but generally known as mefenidil, which bears US NIH Compound Identifier 65475. European Medicines Agency schedules Mefenidil in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB08704MIG. The term MEFENIDIL is an International Non-Proprietary Name.

UNSPSC 51412010 Mefenidil is a Commodity code that captures emergency and acute-care pharmaceuticals—specifically vasodilators and cardiac medications—procured by state and local government health and emergency-services agencies for hospital systems, paramedic fleets, and public-health programs. State and local governments buy mefenidil and related advanced life support medications as line-item pharmaceutical supplies for emergency medical services (EMS) operations, fire rescue departments, and state pharmacy benefit programs. Issuing bodies include city procurement offices managing EMS contracts, state health agencies overseeing pharmacy benefit administration and direct-to-manufacturer prescription initiatives, and regional cooperative purchasing alliances administering multi-jurisdictional pharmaceutical supply agreements. The City of Tampa's Purchasing Department and Texas Health and Human Services Commission represent the mix—municipal EMS buyers executing single-jurisdiction IFBs for specific medication quantities, and state-level health agencies conducting exploratory RFIs and formal RFPs to architect statewide or multi-state pharmaceutical procurement strategies.

Recent activity spans Florida, Texas, and Minnesota. The City of Tampa issued IFB 26P00188 for Advanced Life Support Medications (due April 8, 2026, estimated value $40,000) to supply Tampa Fire Rescue with four medication line items including epinephrine, adenosine, labetalol, and diltiazem, with a 5 percent small local business enterprise bid discount and one-year initial term plus two one-year renewal options. The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), administered by the Minnesota Department of Administration, posted an RFP (due March 26, 2026) to establish multi-award contracts for generic multi-source pharmaceuticals and OTC products distributed across participating state and local government facilities including Oregon, with a July 1, 2026 effective date and two-year initial term. Texas Health and Human Services Commission issued exploratory RFI HHS0017013 (April 3, 2026 deadline) to gather vendor capabilities for a Therapeutic Pharmacy Initiative direct-to-manufacturer prescriptions program, signaling the state's intent to develop formal procurement specifications for later RFP issuance. Mefenidil solicitation activity reflects steady demand for emergency cardiac medications across municipal EMS procurement and state-level therapeutic pharmacy initiatives with multi-year contract horizons and cooperative purchasing leverage.